IJMABHR International Journal of Medical and All Body Health ResearchIJMABHR 2582-8940 Anfo Publication House 220 Formulation and evaluation of metoprolol tartrate transdermal drug patches AnithaMary Rathna KarthikT VaishnaviKothapally ManognaKoppunuru VhishnaviM Assistant Professor, Department of Pharmaceutics, Sree Dattha Institute of Pharmacy, Sheriguda (V), Ibrahimpatnam (M), Ranga Reddy, Telangana, India Sree Dattha Institute of Pharmacy, Sree Datta College Road, Sheriguda, Telangana, India 2024 5 2 22 25 05032024 07042024 CC BY-NC-SA 4.0

The objective of present study was to develop matrix type transdermal therapeutic systems of Metoprolol tartrate using various such as Sodium alginate and HPMC polymers as matrix formers. Results revealed that prepared patches showed good physical characteristics and no drug-polymer interaction was observed. The in vitro release study revealed that F3 formulation showed maximum release in 8 hrs. Formulation F3 was subjected for accelerated stability studies. The F3 formulation was found to be stable as there was no drastic change in the Physico-chemical properties of the patches, which was also confirmed by FTIR. Thus, conclusion can be made that stable transdermal patch of Metoprolol tartrate has been developed. F3 formulation showed highest cumulative percentage drug release of 93.97 % were obtained during in vitro drug release studies after 8 hrs. The predominant release mechanism of drug through the fabricated matrices was believed to be by diffusion mechanism. Based upon the in vitro dissolution data the F3 formulation was concluded as optimized formulation. 

 Metoprolol tartrateSodium alginate and HPMCsolvent casting techniquein vitro drug release studies References Asbill CS, Michniak BB. Percutaneous penetration enhancers: Local versus transdermal activity. Pharm Sci Technolo Today. 2000; 3:36–41. Balaji P, Thirumal M, Gowri R, Divya V, Ramaswamy V. Design and evaluation of matrix type of transdermal patches of methotrexate. Int J Pharm Chem Biol Sci. 2012; 2:464–71. Ashok Kumar. Transdermal drug delivery system: an overview. Int J Pharm Sci Rev Res. 2010 Jul-Aug; 3(2)009. Mounika B. Transdermal drug delivery system with formulation and evaluation aspects: Overview. Res J Pharm Technol. 2012; 5(9):1168-1176. Venkateshwara Reddy B. Formulation and evaluation of carvedilol transdermal patches with hydrophilic polymers. World J Pharm Res. 2014; 3(10):815-826. Shasikanth. Formulation and evaluation of transdermal drug delivery system of carvedilol. J Pharm Res. 2009. Gannu. Development of carvedilol transdermal patches: evaluation of physicochemical, in vivo and mechanical properties. PDA J Pharm Sci Technol. 2008 Nov-Dec; 62(6):391-401. Megha N. Design and evaluation of carvedilol transdermal patch using natural polymers. J Pharm Res. 2012; 5(10):4947-4949. Dinesh Babu. Design and evaluation of valsartan transdermal patches. Int J Res Ayurveda Pharm. 2012 May; 3(3):461-464. Kashinatha BP. Design and evaluation of transdermal film of valsartan by using modified polymer. J Pharm Res. 2012; 5(5):2823-2829. Ekapol. Preparation and evaluation of diltiazem hydrochloride diffusion-controlled transdermal delivery system. AAPS PharmSciTech. 2008 Jun; 9(2):464–470. Jeevanandham S. Formulation and evaluation of dual transdermal patch containing metformin hydrochloride -metoprolol tartarate. Int J Adv Pharm. 2014; 4(3):160-164. Gaikwad AK. Transdermal drug delivery system: Formulation aspects and evaluation- A Review. Compr J Pharm Sci. 2013; 1(1):1-10. Selvam RP, Singh AK, Sivakumar T. Transdermal drug delivery systems for antihypertensive drugs - A review. Int J Pharm Biomed Res. 2010; 1(1):1-8. Copyright and License © The Author(s). Authors retain the copyright of their published articles. This is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution Non Commercial-Share A like 4.0 International (CC BY-NC-SA 4.0) License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.